Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Vaccine|November 12, 2018
Preparing for safety monitoring after rotavirus vaccine introduction - Assessment of baseline epidemiology of intussusception among children <2 years of age in four Asian countriesEleanor Burnett, Nguyen Van Trang, Ajit Rayamajhi, et al.
Frontiers in Immunology|April 10, 2026
Profiling of SARS-CoV-2 virus shedding, antibody neutralization, and T-cell receptor repertoires in a large, multi-center cohort of young adults with varied prior exposuresAndrew Fiore-Gartland, Koshlan Mayer-Blackwell, James Stray, et al.
The Journal of Clinical Investigation|April 3, 2025
Safety and implementation of phase I randomized GLA-SE-adjuvanted CH505TF gp120 HIV vaccine trial in newbornsAvy Violari, Kennedy Otwombe, William Hahn, et al.
Annals of Internal Medicine|April 28, 2025
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)Sharon A Riddler, Zoe Moodie, Jesse Clark, et al.
The Journal of Infectious Diseases|November 23, 2019
Infectious Etiologies of Intussusception Among Children <2 Years Old in 4 Asian CountriesEleanor Burnett, Furqan Kabir, Nguyen Van Trang, et al.
Open Forum Infectious Diseases|November 29, 2023
Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021Kathryn E Stephenson, Jasmine R Marcelin, Audrey E Pettifor, et al.
The Lancet. Global Health|June 16, 2019
Global impact of rotavirus vaccine introduction on rotavirus hospitalisations among children under 5 years of age, 2008-16: findings from the Global Rotavirus Surveillance NetworkNegar Aliabadi, Sébastien Antoni, Jason M Mwenda, et al.
The New England Journal of Medicine|April 19, 2018
Evaluation of Intussusception after Monovalent Rotavirus Vaccination in AfricaJacqueline E Tate, Jason M Mwenda, George Armah, et al.
BMC Immunology|February 18, 2025
Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIVTariro D Chawana, Stephen R Walsh, Lynda Stranix-Chibanda, et al.
The Lancet. HIV|December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
Pageof 8